Monoclonal gammopathy of undetermined significance natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{ Monoclonal gammopathy of undetermined significance }} {{CMG}} ==Overview== ==Natural History== ==Complications== ==Prognosis== * MGUS may be considered a pre-m...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ Monoclonal gammopathy of undetermined significance }} | {{ Monoclonal gammopathy of undetermined significance }} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
{{CMG}} | {{CMG}} | ||
| Line 18: | Line 19: | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs content]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 14:46, 21 September 2012
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance natural history, complications and prognosis |
|
on Monoclonal gammopathy of undetermined significance natural history, complications and prognosis |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Natural History
Complications
Prognosis
- MGUS may be considered a pre-malignant condition, given the possibility of transformation into multiple myeloma. However, because the condition tends to occur in the elderly, and because the rate of progression is slow, only a small proportion of people with MGUS go on to develop ahaematological malignancy. In patients with MGUS, although the actuarial risk of myeloma at 25 years of follow-up is 30%, the actual risk (when competing causes of death are taken into account) is only 11%.[1]
- The annual risk of progressing to multiple myeloma is around 1–2% a year. Kyle et al studied the prevalence of myeloma in a population-wide cohort in Olmsted County, Minnesota. They found that the prevalence of MGUS was 3.2% in people above 50, with a slight male predominance (4.0% vs. 2.7%). Prevalence increased with age: of people over 70 up to 5.3% had MGUS, while in the over-85 age group the prevalence was 7.5%. In the majority of cases (63.5%), the paraprotein level was <1 g/dl, while only a very small group had levels over 2 g/dl.[2]
- In addition to multiple myeloma, MGUS may also progress to Waldenström's macroglobulinemia, primary amyloidosis, B-cell lymphoma, orchronic lymphocytic leukemia. '
References
- ↑ Bladé J (2006). "Clinical practice. Monoclonal gammopathy of undetermined significance". N Engl J Med. 355 (26): 2765–70. PMID 17192542 Abstract.
- ↑ Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. (2006). "Prevalence of monoclonal gammopathy of undetermined significance". N Engl J Med. 354: 1362–9. PMID 16571879. Unknown parameter
|month=ignored (help)